- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare Tata India Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.15 | 1.91 |
NAV | ₹30.17 | ₹38.39 |
Fund Started | 04 Dec 2015 | 25 Jun 2018 |
Fund Size | ₹1287.45 Cr | ₹5320.29 Cr |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.15
1.91
NAV
₹30.17
₹38.39
Fund Started
04 Dec 2015
25 Jun 2018
Fund Size
₹1287.45 Cr
₹5320.29 Cr
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 28.51% | 35.99% |
3 Year | 20.99% | 24.39% |
5 Year | 25.74% | 28.81% |
1 Year
28.51%
35.99%
3 Year
20.99%
24.39%
5 Year
25.74%
28.81%
Holding Analysis
Equity | 94.90% | 98.07% |
Cash | 5.10% | 1.93% |
Equity
94.90%
98.07%
Cash
5.10%
1.93%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.78% |
Aurobindo Pharma Ltd. | 7.68% |
Lupin Ltd. | 7.51% |
Dr. Reddy's Laboratories Ltd. | 6.63% |
Cipla Ltd. | 5.82% |
Divi's Laboratories Ltd. | 4.97% |
Fortis Healthcare Ltd. | 4.78% |
Zydus Lifesciences Ltd. | 3.56% |
Apollo Hospitals Enterprise Ltd. | 3.34% |
Alkem Laboratories Ltd. | 3.29% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Fund Manager
Name | Meeta Shetty | Dharmesh Kakkad |
Start Date | 09 Nov 2018 | 23 Feb 2021 |
Name
Meeta Shetty
Dharmesh Kakkad
Start Date
09 Nov 2018
23 Feb 2021
About Fund
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Dec 2015 | 25 Jun 2018 |
Description
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
04 Dec 2015
25 Jun 2018
